Navigation Links
Yongye Biotechnology to Host 'Virtual Retail Road Show' to Provide Overview of the Company in English and Mandarin
Date:2/14/2009

BEIJING, Feb. 14 /PRNewswire-Asia-FirstCall/ -- Yongye Biotechnology International, Inc. (OTC Bulletin Board: YGYB; "Yongye" or the "Company"), a leading developer, producer and distributor of nutrients for plants and animals, located in the People's Republic of China, today announced that the Company's management will host a conference call and webcast in which it will provide an English language overview of the Company followed by a question and answer session in English and Mandarin. This call will be made available to all individual investors, stock brokers and fund managers who wish to gain a deeper understanding of Yongye's business and growth strategy so as to provide them with the same level of management access and insight enjoyed by fund managers who are able to attend investment banking-sponsored investment conferences.

Hosting the call will be Mr. Zishen Wu, Chairman and CEO, and Mr. Larry Gilmore, Vice President of Corporate Strategy and Principal Financial Officer.

Details of the conference call are:

    Date:                                   February 17, 2009
    Time:                                   7:00 PM Eastern
    North American Dial-in Number:          (866) 203-3436
    International Dial-in Number:           (617) 213-8849
    Passcode:                               108 145 95

The webcast will be accessible at: http://www.ccgirasia.com

The webcast will consist of downloadable conference call presentation materials in either English or Mandarin.

English and Mandarin versions of Yongye's Corporate Profile will also be available for download at: http://www.ccgirasia.com

A replay of the conference call will be available starting at 9:00 PM Eastern on February 17 until March 3, 2009.

To access the replay:

    North American Dial-in Number:     (888) 286-8010
    International Dial-in Number:      (617) 801-6888
    Passcode:                          346 376 28

"We are excited by this opportunity to introduce Yongye to North Americans who are interested in Chinese companies like Yongye," said Mr. Zishen Wu, Chairman and CEO. "We know that there are a large number of people living in North America who speak English and Mandarin who are interested in learning more investment opportunities in China. During the call, we will provide information about what is taking place in China's agricultural sector and what is taking place at our company."

About the Virtual Retail Road Show TM

The Virtual Retail Road Show is designed as a tool to provide individual investors with the same level of access and insight into corporate strategy and market outlook that is currently enjoyed by institutional investors at investment banking conferences and one-on-one meetings on investor road shows. The Virtual Retail Road Show was introduced by CCG Investor Relations to broaden the knowledge of selected growth companies by a broad range of individual investors and stock brokers and level the playing field by providing better access and information to allow informed investment decisions. For more information or to sign up for additional Virtual Retail Road Shows visit www.ccgirasia.com

About Yongye Biotechnology International, Inc.

Yongye Biotechnology International, Inc., headquartered in Beijing, is engaged in the research and development, distribution and sales of fulvic acid based nutrients for plants and animals. The Company's patent pending processes and proprietary formulas allow it to create products that increase crop yields and improve the health of livestock. Its sole operating subsidiary, Yongye Nongfeng Biotechnology Company, Ltd., is located in Inner Mongolia, People's Republic of China. The Company sells its products through distributors and directly to farmers located in ten provinces throughout China.

Safe Harbor Statement

This press release contains certain statements that may include "forward looking statements." All statements other than statements of historical fact included herein are "forward-looking statements." These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, involving known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including the risk factors discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on the SEC's website ( http://www.sec.gov ). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these risk factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

    Contact:
    Yongye Biotechnology International, Inc.
    Mr. Larry Gilmore,VP of Corporate Strategy
    and Principal Financial Officer
    Phone: +86-8232-8866 x 8880
    E-mail: larry.gilmore@gmail.com

    CCG Investor Relations, Inc.
    Mr. Crocker Coulson, President
    Phone: +1-646-213-1915 (New York)
    E-mail: crocker.coulson@ccgir.com
   http://www.ccgirasia.com


'/>"/>
SOURCE Yongye Biotechnology International, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Yongye Biotechnology Completes Reverse Merger and Completes $10.0 Million Private Financing
2. Yongye Biotechnology International, Inc. Appoints New Independent Auditor
3. Yongye Biotechnology International Retains CCG Investor Relations
4. Yongye Biotechnology International Announces Conference Call to Discuss Second Quarter 2008 Results
5. Yongye Biotechnology International Announces Second Quarter Results
6. Yongye Biotechnology International Raises $9.4 Million in Private Placement
7. Letter to Shareholders from the CEO and Chairman of the Board of Yongye Biotechnology, Inc.
8. Yongye Biotechnology to Present at Roth Capital China Comes to Vegas Conference
9. Yongye Biotechnology Announces Record Third Quarter Results
10. Yongye Biotechnology to Present at Roth Conference
11. Yongye Biotechnology International to Expand its Network of Branded Stores
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, the ... the Supplyframe Design Lab . Located in Pasadena, Calif., the Design Lab’s ... how hardware projects are designed, built and brought to market. , The Design ...
(Date:6/23/2016)... ... , ... In a new case report published today in STEM CELLS Translational ... lymphedema after being treated for breast cancer benefitted from an injection of stem cells ... this debilitating, frequent side effect of cancer treatment. , Lymphedema refers to ...
(Date:6/23/2016)... 23, 2016  Blueprint Bio, a company dedicated to ... medical community, has closed its Series A funding round, ... "We have received a commitment from Forentis ... need to meet our current goals," stated Matthew ... runway to complete validation on the current projects in ...
(Date:6/23/2016)... 23, 2016 On Wednesday, June 22, ... down 0.22%; the Dow Jones Industrial Average edged 0.27% lower ... 2,085.45, down 0.17%. Stock-Callers.com has initiated coverage on the following ... Therapeutics (NASDAQ: NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ... BIND ). Learn more about these stocks by accessing ...
Breaking Biology Technology:
(Date:5/12/2016)... DALLAS , May 12, 2016 ... has just published the overview results from the Q1 ... of the recent wave was consumers, receptivity to a ... wearables data with a health insurance company. ... choose to share," says Michael LaColla , CEO ...
(Date:5/3/2016)... 2016  Neurotechnology, a provider of high-precision biometric ... Biometric Identification System (ABIS) , a complete system ... ABIS can process multiple complex biometric transactions with ... fingerprint, face or iris biometrics. It leverages the ... MegaMatcher Accelerator , which have been used ...
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
Breaking Biology News(10 mins):